查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1349442

基於片段的藥物發現市場 - 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢和預測

Fragment Based Drug Discovery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

基於片段的藥物發現市場 - 報告範圍

TMR 關於全球基於片段的藥物發現市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球基於片段的收入2017-2031年藥物發現市場，以2023 年為基準年，2031 年為預測年。該報告也提供了2023年至2031年全球基於片段的藥物發現市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解基於片段的藥物發現市場。

市場概況
2023年市場價值 7.954 億美元
2031 年市場價值 21 億美元
年複合成長率 0.115%

該報告深入研究了全球基於片段的藥物發現市場的競爭格局。全球基於片段的藥物發現市場的主要參與者已經確定，並且每個參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球基於片段的藥物發現市場參與者的屬性。

目錄

第一章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 技術進步
  • 重要行業活動
  • 按地區/全球分類的監管情景
  • 主要研究機構參與
  • COVID-19 大流行對產業的影響（價值鍊和短期/中期/長期影響）

第 6 章：全球市場分析與預測：按組成部分

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按組成部分，2017-2031
    • 片段篩選
      • 生物物理技術
        • 核磁共振波譜
        • 差示掃描螢光法 (DSF) 測定
        • 螢光偏振
        • 等溫滴定量熱法
        • X光晶體學
        • 表面等離子共振 (SPR)
        • 雙層干涉測量法
        • 質譜 (MS)
        • 毛細管電泳
        • 弱親和層析法 (WAC - HPLC-UV/MS)
        • 其他測定（生化）
      • 非生物物理技術
    • 片段最佳化
  • 市場吸引力分析：按組成部分

第 7 章：全球市場分析與預測：按應用分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依應用分類，2017-2031
    • 腫瘤學
    • 中樞神經系統 (CNS) 疾病
    • 傳染性疾病
    • 心血管疾病
    • 代謝紊亂
    • 發炎與自體免疫疾病
  • 市場吸引力分析：按應用

第 8 章：全球市場分析與預測：按最終用戶

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2017-2031
    • 學術研究機構
    • 製藥與生物技術公司
    • 合約研究組織 (CRO)
  • 市場吸引力分析：按最終用戶

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美全球市場分析與預測

第 11 章：歐洲全球市場分析與預測

第 12 章：亞太地區全球市場分析與預測

第 13 章：拉丁美洲全球市場分析與預測

第 14 章：中東和非洲全球市場分析與預測

第 15 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類，2021 年
  • 公司簡介
    • Alveus Pharmaceuticals Pvt. Ltd.
    • Astex Pharmaceuticals
    • Charles River Laboratories International, Inc.
    • Beactica AB
    • Emerald BioStructures, Inc.
    • Crown Bioscience, Inc.
    • Evotec AG
    • Proteros Fragments GmbH
    • Kinetic Discovery Limited
    • Sprint Bioscience
    • Sygnature Discovery
    • Structure Based Design, Inc.
Product Code: TMRGL4741

Fragment Based Drug Discovery Market - Scope of Report

TMR's report on the global fragment based drug discovery market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global fragment based drug discovery market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fragment based drug discovery market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the fragment based drug discovery market.

Market Snapshot
Market Value in 2023US$ 795.4 Mn
Market Value in 2031US$ 2.1 Bn
CAGR11.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global fragment based drug discovery market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global fragment based drug discovery market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global fragment based drug discovery market.

The report delves into the competitive landscape of the global fragment based drug discovery market. Key players operating in the global fragment based drug discovery market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global fragment based drug discovery market profiled in this report.

Key Questions Answered in Global Fragment Based Drug Discovery Market Report:

  • What is the sales/revenue generated by fragment based drug discovery across all regions during the forecast period?
  • What are the opportunities in the global fragment based drug discovery market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Fragment Based Drug Discovery Market - Research Objectives and Research Approach

The comprehensive report on the global fragment based drug discovery market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global fragment based drug discovery market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global fragment based drug discovery market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fragment Based Drug Discovery Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Fragment Based Drug Discovery Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Key Industry Events
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. Major Research Institutes Involved
  • 5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Component

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Component, 2017-2031
    • 6.3.1. Fragment Screening
      • 6.3.1.1. Biophysical Techniques
        • 6.3.1.1.1. NMR Spectroscopy
        • 6.3.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 6.3.1.1.3. Fluorescence Polarization
        • 6.3.1.1.4. Isothermal Titration Calorimetry
        • 6.3.1.1.5. X-ray Crystallography
        • 6.3.1.1.6. Surface Plasmon Resonance (SPR)
        • 6.3.1.1.7. Bilayer Interferometry
        • 6.3.1.1.8. Mass Spectrometry (MS)
        • 6.3.1.1.9. Capillary Electrophoresis
        • 6.3.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 6.3.1.1.11. Other Assays (Biochemical)
      • 6.3.1.2. Non-biophysical Techniques
    • 6.3.2. Fragment Optimization
  • 6.4. Market Attractiveness Analysis, by Component

7. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Oncology
    • 7.3.2. Central Nervous System (CNS) Disorders
    • 7.3.3. Infectious Diseases
    • 7.3.4. Cardiovascular Diseases
    • 7.3.5. Metabolic Disorders
    • 7.3.6. Inflammation & Autoimmune Diseases
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Fragment Based Drug Discovery Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2017-2031
    • 8.3.1. Academic & Research Institutions
    • 8.3.2. Pharmaceutical & Biotechnology Companies
    • 8.3.3. Contract Research Organizations (CROs)
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Component, 2017-2031
    • 10.2.1. Fragment Screening
      • 10.2.1.1. Biophysical Techniques
        • 10.2.1.1.1. NMR Spectroscopy
        • 10.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 10.2.1.1.3. Fluorescence Polarization
        • 10.2.1.1.4. Isothermal Titration Calorimetry
        • 10.2.1.1.5. X-ray Crystallography
        • 10.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 10.2.1.1.7. Bilayer Interferometry
        • 10.2.1.1.8. Mass Spectrometry (MS)
        • 10.2.1.1.9. Capillary Electrophoresis
        • 10.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 10.2.1.1.11. Other Assays (Biochemical)
      • 10.2.1.2. Non-biophysical Techniques
    • 10.2.2. Fragment Optimization
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Oncology
    • 10.3.2. Central Nervous System (CNS) Disorders
    • 10.3.3. Infectious Diseases
    • 10.3.4. Cardiovascular Diseases
    • 10.3.5. Metabolic Disorders
    • 10.3.6. Inflammation & Autoimmune Diseases
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Academic & Research Institutions
    • 10.4.2. Pharmaceutical & Biotechnology Companies
    • 10.4.3. Contract Research Organizations (CROs)
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Component
    • 10.6.2. By Application
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Component, 2017-2031
    • 11.2.1. Fragment Screening
      • 11.2.1.1. Biophysical Techniques
        • 11.2.1.1.1. NMR Spectroscopy
        • 11.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 11.2.1.1.3. Fluorescence Polarization
        • 11.2.1.1.4. Isothermal Titration Calorimetry
        • 11.2.1.1.5. X-ray Crystallography
        • 11.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 11.2.1.1.7. Bilayer Interferometry
        • 11.2.1.1.8. Mass Spectrometry (MS)
        • 11.2.1.1.9. Capillary Electrophoresis
        • 11.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 11.2.1.1.11. Other Assays (Biochemical)
      • 11.2.1.2. Non-biophysical Techniques
    • 11.2.2. Fragment Optimization
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Oncology
    • 11.3.2. Central Nervous System (CNS) Disorders
    • 11.3.3. Infectious Diseases
    • 11.3.4. Cardiovascular Diseases
    • 11.3.5. Metabolic Disorders
    • 11.3.6. Inflammation & Autoimmune Diseases
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Academic & Research Institutions
    • 11.4.2. Pharmaceutical & Biotechnology Companies
    • 11.4.3. Contract Research Organizations (CROs)
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Component
    • 11.6.2. By Application
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Component, 2017-2031
    • 12.2.1. Fragment Screening
      • 12.2.1.1. Biophysical Techniques
        • 12.2.1.1.1. NMR Spectroscopy
        • 12.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 12.2.1.1.3. Fluorescence Polarization
        • 12.2.1.1.4. Isothermal Titration Calorimetry
        • 12.2.1.1.5. X-ray Crystallography
        • 12.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 12.2.1.1.7. Bilayer Interferometry
        • 12.2.1.1.8. Mass Spectrometry (MS)
        • 12.2.1.1.9. Capillary Electrophoresis
        • 12.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 12.2.1.1.11. Other Assays (Biochemical)
      • 12.2.1.2. Non-biophysical Techniques
    • 12.2.2. Fragment Optimization
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Oncology
    • 12.3.2. Central Nervous System (CNS) Disorders
    • 12.3.3. Infectious Diseases
    • 12.3.4. Cardiovascular Diseases
    • 12.3.5. Metabolic Disorders
    • 12.3.6. Inflammation & Autoimmune Diseases
  • 12.4. Market Value Forecast, by End-user, 2017-2031
    • 12.4.1. Academic & Research Institutions
    • 12.4.2. Pharmaceutical & Biotechnology Companies
    • 12.4.3. Contract Research Organizations (CROs)
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Component
    • 12.6.2. By Application
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Component, 2017-2031
    • 13.2.1. Fragment Screening
      • 13.2.1.1. Biophysical Techniques
        • 13.2.1.1.1. NMR Spectroscopy
        • 13.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 13.2.1.1.3. Fluorescence Polarization
        • 13.2.1.1.4. Isothermal Titration Calorimetry
        • 13.2.1.1.5. X-ray Crystallography
        • 13.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 13.2.1.1.7. Bilayer Interferometry
        • 13.2.1.1.8. Mass Spectrometry (MS)
        • 13.2.1.1.9. Capillary Electrophoresis
        • 13.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 13.2.1.1.11. Other Assays (Biochemical)
      • 13.2.1.2. Non-biophysical Techniques
    • 13.2.2. Fragment Optimization
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Oncology
    • 13.3.2. Central Nervous System (CNS) Disorders
    • 13.3.3. Infectious Diseases
    • 13.3.4. Cardiovascular Diseases
    • 13.3.5. Metabolic Disorders
    • 13.3.6. Inflammation & Autoimmune Diseases
  • 13.4. Market Value Forecast, by End-user, 2017-2031
    • 13.4.1. Academic & Research Institutions
    • 13.4.2. Pharmaceutical & Biotechnology Companies
    • 13.4.3. Contract Research Organizations (CROs)
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Component
    • 13.6.2. By Application
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Component, 2017-2031
    • 14.2.1. Fragment Screening
      • 14.2.1.1. Biophysical Techniques
        • 14.2.1.1.1. NMR Spectroscopy
        • 14.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 14.2.1.1.3. Fluorescence Polarization
        • 14.2.1.1.4. Isothermal Titration Calorimetry
        • 14.2.1.1.5. X-ray Crystallography
        • 14.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 14.2.1.1.7. Bilayer Interferometry
        • 14.2.1.1.8. Mass Spectrometry (MS)
        • 14.2.1.1.9. Capillary Electrophoresis
        • 14.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 14.2.1.1.11. Other Assays (Biochemical)
      • 14.2.1.2. Non-biophysical Techniques
    • 14.2.2. Fragment Optimization
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Oncology
    • 14.3.2. Central Nervous System (CNS) Disorders
    • 14.3.3. Infectious Diseases
    • 14.3.4. Cardiovascular Diseases
    • 14.3.5. Metabolic Disorders
    • 14.3.6. Inflammation & Autoimmune Diseases
  • 14.4. Market Value Forecast, by End-user, 2017-2031
    • 14.4.1. Academic & Research Institutions
    • 14.4.2. Pharmaceutical & Biotechnology Companies
    • 14.4.3. Contract Research Organizations (CROs)
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Component
    • 14.6.2. By Application
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Alveus Pharmaceuticals Pvt. Ltd.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Astex Pharmaceuticals
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Charles River Laboratories International, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Beactica AB
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Emerald BioStructures, Inc.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Crown Bioscience, Inc.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Evotec AG
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Proteros Fragments GmbH
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Kinetic Discovery Limited
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Sprint Bioscience
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Sygnature Discovery
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Structure Based Design, Inc.
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis
      • 15.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 02: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 03: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 04: Global Fragment Based Drug Discovery Market Size (US$ Million) Forecast, by Region, 2017-2031
  • Table 05: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country, 2017-2031
  • Table 06: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 07: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 08: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 09: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 11: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 12 Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 13: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 15: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 17: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 19: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 20: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 21: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 23: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 24: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01. Global Fragment Based Drug Discovery Market Size (US$ Million) and Distribution, by Region, 2022 and 2031
  • Figure 02: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, 2017-2031
  • Figure 03: Global Fragment Based Drug Discovery Market Value Share, by Component (2022)
  • Figure 04: Global Fragment Based Drug Discovery Market Value Share, by Application (2022)
  • Figure 05: Global Fragment Based Drug Discovery Market Value Share, by End-user (2022)
  • Figure 06: Global Fragment Based Drug Discovery Market Value Share, by Component, 2022 and 2031
  • Figure 07: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Fragment Screening, 2017-2031
  • Figure 08: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Fragment Optimization, 2017-2031
  • Figure 09: Global Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 10: Global Fragment Based Drug Discovery Market Value Share, by Application, 2022 and 2031
  • Figure 11: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Oncology, 2017-2031
  • Figure 12: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Central Nervous System (CNS) Disorders, 2017-2031
  • Figure 13: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Infectious Diseases, 2017-2031
  • Figure 19: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Cardiovascular Diseases, 2017-2031
  • Figure 14: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Metabolic Disorders, 2017-2031
  • Figure 15: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Inflammation & Autoimmune Diseases, 2017-2031
  • Figure 16: Global Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 17: Global Fragment Based Drug Discovery Market Value Share, by End-user, 2022 and 2031
  • Figure 18: Global Fragment Based Drug Discovery Market Revenue (US$ Million) and Y-o-Y Growth (%) Forecast, by Academic & Research Institutions, 2017-2031
  • Figure 19: Global Fragment Based Drug Discovery Market Revenue (US$ Million) and Y-o-Y Growth (%) Forecast, by Pharmaceutical & Biotechnology Companies, 2017-2031
  • Figure 20: Global Fragment Based Drug Discovery Market Revenue (US$ Million) and Y-o-Y Growth (%) Forecast, by Contract Research Organizations (CROs), 2017-2031
  • Figure 21: Global Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 22: Global Fragment Based Drug Discovery Market Value Share, by Region, 2022 and 2031
  • Figure 23: Global Fragment Based Drug Discovery Market Attractiveness, by Region, 2017-2031
  • Figure 24: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%) 2017-2031
  • Figure 25: North America Fragment Based Drug Discovery Market Value Share, by Country, 2022 and 2031
  • Figure 26: North America Fragment Based Drug Discovery Market Attractiveness, by Country, 2017-2031
  • Figure 27: North America Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 28: North America Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 29: North America Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 30: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 31: Europe Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031
  • Figure 32: Europe Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031
  • Figure 33: Europe Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 34: Europe Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 35: Europe Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 36: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 37: Asia Pacific Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031
  • Figure 38: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031
  • Figure 39: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 40: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 41: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 42: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 43: Latin America Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031
  • Figure 44: Latin America Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031
  • Figure 45: Latin America Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 46: Latin America Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 47: Latin America Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 48: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 49: Middle East & Africa Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031
  • Figure 50: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031
  • Figure 51: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 52: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 53: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031